High dosage metolazone in chronic renal failure.
Metolazone is a modified quinazolinesulphonamide and in a dose of between 4 and 7.5 mg is an effective diuretic in man with normal renal function. Fourteen patients with non-oedematous stable chronic renal failure (creatinine clearance ranging from 1.2 to 12 ml/min) were given metolazone in doses ranging from 20-150 mg. A noticeable increase in urine flow and sodium excretion occurred, free water clearance increased, and there was a small but significant increase in potassium excretion. No side effects were noted.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D003404:Creatinine / Q000378:metabolism; D004232:Diuretics / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D007659:Ketones / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D007690:Polycystic Kidney Diseases / Q000188:drug therapy; D011188:Potassium / Q000652:urine; D011704:Pyelonephritis / Q000188:drug therapy; D011799:Quinazolines / Q000008:administration & dosage* / Q000627:therapeutic use; D012964:Sodium / Q000652:urine; D013449:Sulfonamides / Q000008:administration & dosage* / Q000627:therapeutic use; D014554:Urination / Q000187:drug effects
D004232:Diuretics; D007659:Ketones; D011799:Quinazolines; D013449:Sulfonamides; D012964:Sodium; D003404:Creatinine; D011188:Potassium